Staphylococcal toxic shock syndrome in a child with interleukin‐17 inhibitor treatment for psoriasis

A 6‐year‐old girl presented with fever, skin rash, anuria, and conjunctivitis that rapidly progressed to toxic shock syndrome. Following hospital discharge, she developed a staphylococcal abscess on the lower extremity. She had recently received the first two doses of the interleukin‐17 (IL‐17) inhibitor secukinumab for resistant plaque psoriasis. IL‐17 is known to be essential in host defense against Staphylococcus aureus. To our knowledge, this is the first reported case of staphylococcal toxic shock syndrome (STSS) associated with an IL‐17 inhibitor.